Raunak Shrestha,
LN Chesner,
M Zhang,
S Zhou,
A Foye,
A Lundberg,
AS Weinstein,
M Sjostrom,
X Zhu,
T Moreno-Rodriguez,
H Li,
JJ Alumkal,
R Aggarwal,
EJ Small,
M Lupien,
DA Quigley,
FY Feng
(2024).
An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression.
Cancer Research.
M Zhang,
M Sjostrom,
X Cui,
A Foye,
K Farh,
Raunak Shrestha,
A Lundberg,
HX Dang,
PG Febbo,
R Aggarwal,
J Alkumal,
EJ Small,
CA Maher,
FY Feng,
DA Quigley
(2024).
Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression.
Nature Cell Biology.
S Zhao,
M Bootsma,
S Zhou,
Raunak Shrestha,
T Moreno-Rodriguez,
A Lundberg,
C Pan,
C Arlidge,
J Hawley,
A Foye,
A Weinstein,
M Sjostrom,
M Zhang,
H Li,
LN Chesner,
N Rydzewski,
K Helzer,
Y Shi,
S Dehm,
J Lang,
J Alumkal,
H He,
A Wyatt,
R Aggarwal,
W Zwart,
E Small,
D Quigley,
M Lupien,
FY Feng
(2024).
Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer.
Nature Genetics.
A Lundberg,
M Zhang,
R Aggarwal,
H Li,
L Zhang,
A Foye,
M Sjostrom,
J Chou,
K Chang,
T Moreno-Rodriguez,
Raunak Shrestha,
A Baskin,
X Zhu,
AS Weinstein,
N Younger,
JJ Alumkal,
TM Beer,
KN Chi,
CP Evans,
M Gleave,
PN Lara,
RE Reiter,
MB Rettig,
ON Witte,
AW Wyatt,
FY Feng,
EJ Small,
DA Quigley
(2023).
The genomic and epigenomic landscape of double-negative metastatic prostate cancer.
Cancer Research.
M Sjostrom,
SG Zhao,
S Levy,
M Zhang,
Y Ning,
Raunak Shrestha,
A Lundberg,
C Herberts,
A Foye,
R Aggarwal,
JT Hua,
H Li,
A Bergamaschi,
C Maurice-Dror,
A Maheshwari,
S Chen,
SWS Ng,
W Ye,
J Petricca,
M Fraser,
L Chesner,
MD Perry,
T Moreno-Rodriguez,
WS Chen,
JJ Alumkal,
J Chou,
AK Morgans,
TM Beer,
GV Thomas,
M Gleave,
P Lloyd,
T Phillips,
E McCarthy,
MC Haffner,
A Zoubeidi,
M Annala,
RE Reiter,
MB Rettig,
ON Witte,
L Fong,
R Bose,
FW Huang,
J Luo,
A Bjartell,
JM Lang,
NP Mahajan,
PN Lara,
CP Evans,
PT Tran,
EM Posadas,
C He,
X Cui,
J Huang,
W Zwart,
LA Gilbert,
CA Maher,
PC Boutros,
KN Chi,
A Ashworth,
EJ Small,
HH He,
AW Wyatt,
DA Quigley,
FY Feng
(2022).
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
Cancer Research.
N Rydzewski,
JM Lang,
M Yu,
M Sjostrom,
SL Chang,
W Chen,
Raunak Shrestha,
M Zhang,
DA Quigley,
R Aggarwal,
E Small,
DR Wahl,
FY Feng,
SG Zhao
(2021).
Predicting Cancer Drug TARGETS - TreAtment Response GlmnET Signatures.
NPJ genomic medicine.
R Das,
M Sjostrom,
Raunak Shrestha,
C Yogodzinski,
EA Egusa,
L Chesner,
WS Chen,
J Chou,
DK Dang,
JT Swinderman,
A Ge,
JT Hua,
S Kabir,
DA Quigley,
EJ Small,
A Ashworth,
FY Feng,
LA Gilbert
(2021).
An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer.
Nature Communications.
Raunak Shrestha,
M Llaurado Fernandez,
A Dawson,
J Hoenisch,
S Volik,
Y Lin,
S Anderson,
H Kim,
A Haegert,
S Colborne,
N Wong,
B McConeghy,
RH Bell,
S Brahmbhatt,
C Lee,
GE DiMattia,
S Le Bihan,
GB Morin,
CC Collins,
MS Carey
(2021).
Multiomics Characterization of Low-grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK-inhibitor Sensitivity and Therapeutic Vulnerability.
Cancer Research.
WS Chen,
WA Haynes,
R Waitz,
K Kamath,
A Vega-Crespo,
Raunak Shrestha,
A Foye,
IB Carretero,
IG Perez,
M Zhang,
SG Zhao,
M Sjostrom,
DA Quigley,
J Chou,
TM Beer,
M Rettig,
M Gleave,
CP Evans,
P Lara,
KN Chi,
RE Reiter,
JJ Alumkal,
R Aggarwal,
EJ Small,
PS Daugherty,
A Ribas,
DY Oh,
JC Shon,
FY Feng
(2020).
Autoantibody landscape in patients with advanced prostate cancer.
Clinical Cancer Research.
Raunak Shrestha,
N Nabavi,
S Volik,
S Anderson,
A Haegert,
B McConeghy,
F Sar,
S Brahmbhatt,
RH Bell,
S Le Bihan,
Y Wang,
CC Collins,
A Churg
(2020).
Well-Differentiated Papillary Mesothelioma of the Peritoneum is Genetically Distinct from Malignant Mesothelioma.
Cancers.
NM D'Costa,
MR Lowerison,
PA Raven,
Z Tan,
ME Roberts,
Raunak Shrestha,
MW Urban,
CU Monjaras-Avila,
HZ Oo,
A Hurtado-Coll,
C Chavez-Munoz,
AI So
(2020).
Y-box Binding Protein-1 is Crucial in Acquired Drug Resistance Development in Metastatic Clear-Cell Renal Cell Carcinoma.
Journal of Experimental & Clinical Cancer Research.
NM D'Costa,
D Cina,
Raunak Shrestha,
RH Bell,
YLin,
H Asghari,
CU Monjaras-Avila,
C Kollmannsberger,
F Hach,
CI Chavez-Munoz,
AI So
(2020).
Identification of Predictive Gene Signature to Guide Precision Oncology of Clear-Cell Renal Cell Carcinoma.
Scientific Reports.
MA Reyna,
D Haan,
M Paczkowska,
LPC Verbeke,
M Vazquez,
A Kahraman,
S Pulido-Tamayo,
J Barenboim,
L Wadi,
P Dhingra,
Raunak Shrestha,
G Getz,
MS Lawrence,
JS Pedersen,
MA Rubin,
DA Wheeler,
S Brunak,
JMG Izarzugaza,
E Khurana,
K Marchal,
C von Mering,
SC Sahinalp,
A Valencia,
J Reimand,
JM Stuart,
BJ Raphael,
PCAWG Consortium
(2020).
Pathway and network analysis of more than 2,500 whole cancer genomes.
Nature Communications.
Raunak Shrestha,
N Nabavi,
Y Lin,
F Mo,
S Anderson,
S Volik,
H H Adomat,
D Lin,
H Xue,
X Dong,
R Shukin,
RH Bell,
B McConeghy,
A Haegert,
S Brahmbhatt,
E Li,
HZ Oo,
A Hurtado-Coll,
L Fazli,
J Zhou,
Y McConnell,
A McCart,
A Lowy,
GB Morin,
T Chen,
M Daugaard,
SC Sahinalp,
F Hach,
S Le Bihan,
ME Gleave,
Y Wang,
A Churg,
CC Collins
(2019).
BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma.
Genome Medicine.
EE Gill,
LS Chan,
GL Winsor,
N Dobson,
R Lo,
SJH Sui,
BK Dhillon,
PK Taylor,
Raunak Shrestha,
CoSpencer,
REW Hancock,
PJ Unrau,
FSL Brinkman
(2018).
High-throughput detection of RNA processing in bacteria.
BMC Genomics.
M Yamada,
J Tang,
J Lugo-Martinez,
E Hodzic,
Raunak Shrestha,
A Saha,
H Ouyang,
D Yin,
H Mamitsuka,
SC Sahinalp,
P Radivojac,
F Menczer,
Y Chang
(2018).
Ultra High-Dimensional Nonlinear Feature Selection for Big Biological Data.
IEEE Transactions on Knowledge and Data Engineering.
Raunak Shrestha,
E Hodzic,
T Sauerwald,
P Dao,
K Wang,
J Yeung,
S Anderson,
F Vandin,
G Haffari,
CC Collins,
SC Sahinalp
(2017).
HIT'nDRIVE: Patient-Specific Multi-Driver Gene Prioritization for Precision Oncology.
Genome Research.
ISU Luk,
Raunak Shrestha,
H Xue,
F Zhang,
D Lin,
A Haegert,
R Wu,
X Dong,
CC Collins,
A Zoubeidi,
ME Gleave,
PW Gout,
Y Wang
(2016).
BIRC6-targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer.
Clinical Cancer Research.
AW Wyatt,
F Mo,
K Wang,
B McConeghy,
S Brahmbhatt,
L Jong,
DM Mitchell,
RL Johnston,
A Haegert,
E Li,
J Liew,
J Yeung,
Raunak Shrestha,
A Lapuk,
A McPherson,
R Shukin,
RH Bell,
S Anderson,
J Bishop,
A Hurtado-Coll,
H Xiao,
AM Chinnaiyan,
R Mehra,
D Lin,
Y Wang,
L Fazli,
ME Gleave,
S Volik,
CC Collins
(2014).
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.
Genome Biology.
Raunak Shrestha,
E Hodzic,
J Yeung,
K Wang,
T Sauerwald,
P Dao,
S Anderson,
H Beltran,
MA Rubin,
CC Collins,
G Haffari,
SC Sahinalp
(2014).
HIT'nDRIVE: Multi-driver gene prioritization based on hitting time.
RECOMB-2014.